For adults with moderate to severe UC or CD1
Their UC and CD goals are in reach and so are yours with Omvoh
Bowel urgency reduction. Long-term remission regardless of biologic exposure.
Reach your goals with Omvoh - an IL-23p19 antagonist for adults with moderately to severely active UC or CD1
Ulcerative Colitis
Crohn's Disease
Lasting Efficacy2,3
Ulcerative Colitis
UC: Clinical remission, endoscopic improvement, and HEMR maintained at 4 years.6,7Crohn's Disease
CD: Clinical remission and endoscopic response maintained at 2 years.3Consistent Efficacy Regardless of Biologic Experience1
Ulcerative Colitis
UC: Clinical remission at Week 52 in overall patients and biologic-experience subgroups (bio-naïve and bio-failure).1Crohn's Disease
CD: Clinical remission at Week 52 in overall patients and biologic-experience subgroups (bio-naïve and bio-failure).1Improvement in Disruptive Symptoms1,2,4,5
Ulcerative Colitis
UC: Bowel urgency improvement as early as Week 2 and sustained through 4 years.6,7Crohn's Disease
CD: Bowel urgency improvement as early as Week 6 and sustained through 2 years.1,3,4,7
DosingUlcerative Colitis
In-label flexible dosing in UC, with extended induction and re-induction.1Crohn's Disease
Indication-optimized, with patients in mind.1Safety Demonstrated Across Multiple Studies for Two Indications UC and CD1
Bio-failure=biologic-failure; bio-naïve=biologic-naïve; CD=Crohn's disease; HEMR=histologic endoscopic mucosal remission; IL=interleukin; UC=ulcerative colitis.
Stay in the Loop with Fresh Updates!
Learn more about how Omvoh can help your UC patients with their most burdensome symptom
The VIVID-1 Study: understanding the long-term effects of Omvoh in active Crohn's disease
Omvoh offers comprehensive management for your patients with Crohn's disease
Long-term remission up to 4 years in patients with moderately to severely active UC with Omvoh
Omvoh offers in-label flexible dosing to help meet your patients' needs
Extended induction with Omvoh increased clinical response to 80.3% at Week 24
What's New? Watch Now.
Learn more about how Omvoh can help your UC patients with their most burdensome symptom.
Prof. Marc Ferrante
VIVID-2 — key efficacy data in CD
Dr. Alissa Walsh
Patient case
Prof. Sebastian Zeissig
Patient case — bio-naïve UC
Prof. Sebastian Zeissig
Patient case — TL Experience
Dr. Tim Raine
ECCO 2024 post-congress
Prof. Vipul Jairath
CD launch burst — mirikizumab vs ustekinumab
Bio-failure = biologic-failure; bio-naïve = biologic-naïve; CD = Crohn's disease; HEMR = histologic endoscopic mucosal remission; IL = interleukin; UC = ulcerative colitis.
- Omvoh EUSPC FEB 2025.
- Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Gibble TH, et al. Three-year efficacy and safety of mirikizumab following 152 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study. Inflammatory Bowel Diseases. Published online October 25, 2024; Epub: izae253.
- Barnes EL, Sands BE, D'Haens G, Hisamatsu T, Kelly CR, Lu N, et al. Long-term efficacy and safety of mirikizumab following 104 weeks of continuous treatment for Crohn's disease: VIVID-2 open-label extension study. CCC; February 6–8, 2025.
- Jairath V, et al. Oral presentation at: ECCO 2024. Abstract OP0550.
- Data on File. REF-72116. Eli Lilly and Company.
- Sands BE, et al. Inflamm Bowel Dis. 2025;31(7):1876–1890.
- Data on file, REF-75768, Eli Lilly and Company.